Showing posts from February, 2021

Ivermectin and COVID-19: Why it’s promising

Doctors around the world has been reporting high success rates using an inexpensive anti-parasitic treatment for COVID-19.  In April last year, a trial at Melbourne’s Monash University  reported  doses of ivermectin stopped or slowed the spread of Covid-19 infection in the lab environment. The researchers said the findings could not be immediately applied to humans but the drug still surged in popularity across  Peru, Bolivia, Guatemala and other Latin American countries . Another study  published in June 2020 by Nature , ivermectin was found to have antiviral activity against a range of viruses including Avian influenza A, Porcine Reproductive and Respiratory Syndrome, HIV, and SARS-Cov-2. The medical community is battling over whether ivermectin should be used to treat and prevent COVID-19. On one side are experts telling you that more research is needed before the treatment can be fully authorised. On the other, are experts telling you that the potential benefits outweigh the risk.

Ivermectin and COVID-19: Meta Analysis of 36 studies (February 2021)

At-A-Glance: 100% of the 36 studies to date report positive effects. Early treatment is more successful, with an estimated reduction of 82% in the effect measured using a random effects meta-analysis, RR 0.18 [0.10-0.34]. Prophylactic use also shows high effectiveness. 100% of the 18 Randomized Controlled Trials (RCTs) report positive effects, with an estimated reduction of 71%, RR 0.29 [0.17-0.50]. The probability that an ineffective treatment generated results as positive as the 36 studies to date is estimated to be 1 in 69 billion (p = 0.000000000015). Introduction We analyze all significant studies concerning the use of ivermectin for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, for studies within each treatment stage, for mortality results only, and for Rand